A randomized, double-blind, one-week study comparing effects of a novel COX-2 inhibitor and naproxen on the gastric mucosa

Digestive Diseases and Sciences

Volumn 52, Issue 2, 2007, Pages 442-450

  Moberly, James B ^a   Harris, Stuart I ^b   Riff, Dennis S ^c   Dale, James Craig ^d   Breese, Tara ^d   McLaughlin, Patrick ^c   Lawson, Janet ^d   Wan, Yaping ^d   Xu, Jianbo ^a   Truitt, Kenneth E ^a  

^a DAIICHI SANKYO INC   (United States)

^b SeaView Research   (United States)

^c Advanced Clinical Research Institute   (United States)

^d Premier Research   (United States)

Author keywords

Cyclooxygenase; Erosions; NSAID induced ulcers; Prostaglandin; Thromboxane; Upper GI endoscopy

Indexed keywords

CS 706; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM INJURY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; GASTRODUODENAL ULCER; GASTROINTESTINAL ENDOSCOPY; HUMAN; MALE; NAUSEA; NORMAL HUMAN; PETECHIA; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH EROSION; STOMACH MUCOSA LESION; UPPER ABDOMINAL PAIN; UREA NITROGEN BLOOD LEVEL;

ADULT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DUODENAL ULCER; DUODENUM; ENDOSCOPY, GASTROINTESTINAL; FEMALE; GASTRIC MUCOSA; HUMANS; INTESTINAL MUCOSA; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NAPROXEN; PYRROLES; REFERENCE VALUES; STOMACH ULCER; SULFONAMIDES; TIME FACTORS; UNITED STATES;

EID: 33846785473     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9521-6     Document Type: Article

References (29)

1. Cronstein BN (2002) Cyclooxygenase-2-selective inhibitors: translating pharmacology into clinical utility. Cleve Clin J Med 69(Suppl 1):SI 13-SI 19
2. Langman MJ, Weil J, Wainwright P, et al. (1994) Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 343:1075-1078
3. Fries JF (1991) NSAID gastropathy: The second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 18(28):6-10
4. Simon LS, Weaver AL, Graham DY, et al. (1999) Antiinflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 282:1921-1928
5. Silverstein FE, Faich G, Goldstein JL, et al. (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284:1247-1255
6. Goldstein JL, Correa P, Zhao WW, et al. (2001) Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 96:1019-1027
7. Laine L, Harper S, Simon T, et al. (1999) A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 117:776-783
8. Bresalier RS, Sandler RS, Quan H, et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092-1102
9. Nussmeier NA, Whelton AA, Brown MT, et al. (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352:1081-1091
10. Graham DJ, Campen D, Hui R, et al. (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase-2 selective and non-selective non-steroidal antiinflammatory drugs: nested case-control study. Lancet 365:475-481
11. Antman EA, DeMets D, Loscalzo J (2005) Cyclooxygenase inhibitors and cardiovascular risk. Circulation 112:759-770
12. Dannenberg A, Altorki NK, Boyle JO, et al. (2001) Cyclooxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2:544-551
13. Cannon CP, Curtis SP, Bolognese JA, Laine L (2006) Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: Cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. Am Heart J 152:237-245.
14. Simon LS, Lanza FL, Lipsky PE, et al. (1998) Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arth Rheum 41:1591-1602
15. Oitate M, Hirota T, Koyama K, et al. (2006) Covalent binding of radioactivity from [14C]rofecoxib, but not [14C]celecoxib or [14C]CS-706, to the arterial elastin of rats. Drug Metab Dispos 34:1417-1422
16. Kastrissios H, Rohatagi S, Moberly J, et al. (2006) Development of a predictive pharmacokinetic model for a novel cyclooxygenase-2 inhibitor. J Clin Pharm 46:537-548
17. Lanza FL, Rack MF, Simon TJ, et al. (1999) Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther 13:761-767
18. Riendeau D, Percival MD, Brideau C, et al. (2001) Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 296:558-566
19. Harris SI, Kuss M, Hubbard RC, Goldstein JL (2001) Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2- specific inhibitor, compared with ketorolac, naproxen, and placebo. Clin Ther 23:1422-1428
20. Rordorf C, Kellett N, Mair S, et al. (2003) Gastroduodenal tolerability of lumiracoxib vs. placebo and naproxen: a pilot endoscopic study in healthy male subjects. Aliment Pharmacol Ther 18:533-541
21. Bjarnason I, Macpherson A, Rotman H, et al. (1997) A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen. Scand J Gastroenterol 32:126-130
22. Bombardier C, Laine L, Reicin A, et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343:1520-1528
23. Scheiman JM (2002) Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors. Cleve Clin J Med 69(Suppl 1):SI-40-SI-46
24. Brideau C, Kargman S, Liu S, et al. (1996) A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 45:68-74
25. Van Hecken A, Schwartz JI, Depre M, et al. (2000) Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 40:1109-1120
26. Panara MR, Renda G, Sciulli MG, et al. (1999) Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther 290:276-280
27. Blain H, Boileau C, Lapicque F, et al. (2002) Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. Br J Clin Pharmacol 53:255-265
28. Lanza FL, Graham DY, Davis RE, Rack MF (1990) Endoscopic comparison of cimetidine and sucralfate for prevention of naproxen-induced acute gastroduodenal injury. Effect of scoring method. Dig Dis Sci 35:1494-1499
29. Lanza F, Rack MF, Lynn M, et al. (1987) An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa. J Rheumatol 14:338-341